666 related articles for article (PubMed ID: 31409076)
41. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
43. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
[TBL] [Abstract][Full Text] [Related]
44. Risk-reducing salpingo-oophorectomy among Chinese women at increased risk of breast and ovarian cancer.
Feng Z; Zuo K; Ju X; Chen X; Yang W; Wen H; Yu L; Wu X
J Ovarian Res; 2023 Jun; 16(1):125. PubMed ID: 37386498
[TBL] [Abstract][Full Text] [Related]
45. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
[TBL] [Abstract][Full Text] [Related]
46. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
Front Genet; 2021; 12():674094. PubMed ID: 34917121
[No Abstract] [Full Text] [Related]
47. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
[TBL] [Abstract][Full Text] [Related]
48. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
49. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
[TBL] [Abstract][Full Text] [Related]
50. Prevalence of Pathogenic Germline Mutations in 13 Hereditary Cancer-Related Genes in Breast Cancer Patients in Narathiwat Province, Thailand.
Sukpan P; Kanokwiroon K; Sriplung H; Laochareonsuk W; Choochuen P; Auseng N; Wanawanakorn K; Sangkhathat S
Asian Pac J Cancer Prev; 2023 Feb; 24(2):525-530. PubMed ID: 36853301
[TBL] [Abstract][Full Text] [Related]
51. High frequency of pathogenic non-founder germline mutations in
Maksimenko J; Irmejs A; Trofimovičs G; Bērziņa D; Skuja E; Purkalne G; Miklaševičs E; Gardovskis J
Hered Cancer Clin Pract; 2018; 16():12. PubMed ID: 29928469
[TBL] [Abstract][Full Text] [Related]
52. Breast cancer and ovarian cancer genetics.
Edlich RF; Winters KL; Lin KY
J Long Term Eff Med Implants; 2005; 15(5):533-45. PubMed ID: 16218901
[TBL] [Abstract][Full Text] [Related]
53. Prophylactic oophorectomy in women at increased cancer risk.
Domchek SM; Rebbeck TR
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):27-30. PubMed ID: 17218848
[TBL] [Abstract][Full Text] [Related]
54. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:
Hanson H; Kulkarni A; Loong L; Kavanaugh G; Torr B; Allen S; Ahmed M; Antoniou AC; Cleaver R; Dabir T; Evans DG; Golightly E; Jewell R; Kohut K; Manchanda R; Murray A; Murray J; Ong KR; Rosenthal AN; Woodward ER; Eccles DM; Turnbull C; Tischkowitz M; ; Lalloo F
J Med Genet; 2023 May; 60(5):417-429. PubMed ID: 36411032
[TBL] [Abstract][Full Text] [Related]
55. Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome.
This P; de la Rochefordière A; Savignoni A; Falcou MC; Tardivon A; Thibault F; Alran S; Fourchotte V; Fitoussi A; Couturaud B; Dolbeault S; Salmon RJ; Sigal-Zafrani B; Asselain B; Stoppa-Lyonnet D;
Fam Cancer; 2012 Sep; 11(3):473-82. PubMed ID: 22711610
[TBL] [Abstract][Full Text] [Related]
56. Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC).
Fernández Madrigal L; Rodríguez Garcés MY; Jiménez Ruiz FJ
Curr Probl Cancer; 2023 Dec; 47(6):101008. PubMed ID: 37704491
[TBL] [Abstract][Full Text] [Related]
57. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
[TBL] [Abstract][Full Text] [Related]
58. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective.
Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A
Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682
[TBL] [Abstract][Full Text] [Related]
59. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
60. Secondary Prevention in Hereditary Breast and/or Ovarian Cancer Syndromes Other Than BRCA.
Piombino C; Cortesi L; Lambertini M; Punie K; Grandi G; Toss A
J Oncol; 2020; 2020():6384190. PubMed ID: 32733558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
